Wong et al. generated low-affinity humanized EGFR antibodies with the assumption that these antibodies would only transiently bind (monovalently) to low EGFR-expressing healthy cells while the antibodies would stably (bivalently) bind to high EGFR-expressing cancer cells. The gene discussed is EGFR; the disease is cancer.